Two studies attempted to determine whether an ARB added to an ACE inhibitor would contribute favourably to clinical outcomes in CHF.8,9 In the Valsartan Heart Failure Trial (Val-HeFT), the results indicated no significant reduction in mortality but a significant reduction in morbidity.9 These results seem to indicate the potential benefit of combining an ACE inhibitor with an ARB in CHF. This evidence concerns the gene ACE and heart failure.